20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T25268 | Coblopasvir | Others | |
Coblopasvir is a pan-genotypic non-structural protein 5A (NS5A) inhibitor. It can be used to study chronic hepatitis C virus infection. | |||
T4197 | HZ-1157 | HZ1157,DHFR-inhibitor | HCV Protease |
HZ-1157 (DHFR-inhibitor) is a hepatitis C virus (HCV) inhibitor with inhibitory activities toward HCV NS3/4A protease. | |||
T1822 | Clemizole | HCV Protease , Histamine Receptor | |
Clemizole is an H1 histamine receptor antagonist, can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication. | |||
T19862 | Voxilaprevir | HCV Protease | |
Voxilaprevir is an inhibitor of hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease. | |||
T5126 | Glecaprevir | ABT-493 | HCV Protease , SARS-CoV |
Glecaprevir (ABT-493) is an HCV NS3/4A protease inhibitor, (IC50s: 3.5-11.3 nM). | |||
T4547 | Grazoprevir | MK-5172 | HCV Protease , SARS-CoV |
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Ki of 0.01 nM (gt1a), 0.08 nM (gt2a), 0.90 nM (gt3a), 0.01 nM (gt1b), ... | |||
T4474 | Asunaprevir | BMS-650032 | HCV Protease , SARS-CoV |
Asunaprevir (BMS-650032) is an effective hepatitis C virus (HCV) NS3 protease inhibitor. | |||
T1822L | Clemizole hydrochloride | HCV Protease , Histamine Receptor | |
Clemizole hydrochloride is an antagonist for H1 histamine receptor. According to the research, Clemizole hydrochloride can inhibit hepatitis C virus (HCV) replication and NS4B's RNA binding. | |||
T25268L | Coblopasvir dihydrochloride | Coblopasvir dihydrochloride(1312608-46-0 Free base) | HCV Protease |
Coblopasvir dihydrochloride can be used to study chronic HCV infection and is a pan-genotypic nonstructural protein 5A (NS5A) inhibitor. | |||
T4988 | Boceprevir | SCH 503034,EBP 520 | HCV Protease , SARS-CoV |
Boceprevir (SCH 503034) is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay. | |||
T9567 | Samatasvir | ATOLIHZIXHZSBA-BTSKBWHGSA-N,IDX719 | HCV Protease |
Samatasvir (ATOLIHZIXHZSBA-BTSKBWHGSA-N) is a pan-genotypic inhibitor of the HCV non-structural protein 5A. | |||
T22394 | Paritaprevir | ABT450,ABT-450,Veruprevir | HCV Protease |
Paritaprevir (ABT450) is an inhibitor of non-structural protein 3/4A protease with EC50 values of 1 and 0.21 nM for HCV 1a and HCV 1b, respectively. | |||
T6190 | Telaprevir | VX-950,LY-570310,Incivek,MP-424 | HCV Protease , SARS-CoV |
Telaprevir (Incivek) (VX-950) is an effective inhibitor of HCV NS3-4A serine protease (IC50: 0.35 μM). | |||
T4686 | Simeprevir | TMC435,TMC-435350,Olysio | HCV Protease , SARS-CoV |
Simeprevir (TMC435) is a potent HCV NS3/4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM. | |||
T6025 | Danoprevir | R7227,ITMN-191,RG7227,RO5190591 | HCV Protease , SARS-CoV |
Danoprevir (RG7227) is a peptidomimetic inhibitor of the NS3/4A protease(IC50=0.2-3.5 nM) of hepatitis C virus (HCV). | |||
T28830 | Sovaprevir | ACH 0141625,ACH0141625,ACH-0141625,ACH1625,ACH 1625,ACH-1625 | HCV Protease |
Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection. | |||
T3226 | Paritaprevir | ABT-450,Veruprevir | HCV Protease |
Paritaprevir (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity again... | |||
T14555 | BI-1230 | HCV Protease | |
BI-1230 is a potent inhibitor of HCV NS3 protease, exhibiting efficacy in the low nanomolar range, and notably suppresses viral replication. This compound demonstrates high selectivity, distinguishing effectively between... | |||
T71131 | IDX-320 | ||
IDX-320 is an HCV protease inhibitor. | |||
T35043 | Vedroprevir | GS9451,GS 9451,GS-9451 | |
Vedroprevir, also known as GS9451, is a selective hepatitis C virus (HCV) NS3 protease inhibitor in the development of the treatment of genotype 1 (GT1) HCV infection. |